Share the post "Marksans Pharma : Q4 2024 Financial Quarterly Report : YoY Sales Up 15.23 %, QoQ Down 4.46 %"
Highlights
- Sales over the Year and quarter: The company experienced a substantial growth of 15.23 % in the past year, decrease in net sales/revenue by -4.46 %.
- Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 50.14 %. Marginal increase in other income during this quarter, up by 244.38%.
- Profit over the Year and quarter: Challenges in sustaining profitability for Marksans Pharma Ltd.. Profit dropped by -6.13 % Year to Year, Marksans Pharma Ltd.’s profitability dropped by -6.41 % Quarter to Quarter.
- EPS over the Year and quarter: EPS declined by -12.18 % Year to Year. EPS decreased by -5.98 % in previous quarter. Analysis needed for shareholder value.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 485.976 Cr | Rs. 586.127 Cr | Rs. 560.013 Cr | -4.46 % | + 15.23 % |
| Expenses | Rs. 376.43 Cr | Rs. 453.11 Cr | Rs. 450.37 Cr | -0.6 % | + 19.64 % |
| Operating Profit | Rs. 109.55 Cr | Rs. 133.02 Cr | Rs. 109.64 Cr | -17.58 % | + 0.08 % |
| OPM % | 22.54 % | 22.69 % | 19.58 % | -3.11 % | -2.96 % |
| Other Income | Rs. 11.01 Cr | Rs. 4.8 Cr | Rs. 16.53 Cr | + 244.38 % | + 50.14 % |
| Interest | Rs. 2.44 Cr | Rs. 3.16 Cr | Rs. 4.84 Cr | + 53.16 % | + 98.36 % |
| Depreciation | Rs. 13.94 Cr | Rs. 22 Cr | Rs. 21.06 Cr | -4.27 % | + 51.08 % |
| Profit before tax | Rs. 104.18 Cr | Rs. 112.66 Cr | Rs. 100.27 Cr | -11 % | -3.75 % |
| Tax % | 20.6 % | 26.36 % | 22.57 % | -3.79 % | + 1.97 % |
| Net Profit | Rs. 82.71 Cr | Rs. 82.97 Cr | Rs. 77.64 Cr | -6.42 % | -6.13 % |
| EPS in Rs | Rs. 1.97 | Rs. 1.84 | Rs. 1.73 | -5.98 % | -12.18 % |
Today, we’re looking at Marksans Pharma Ltd.’s financial performance for the Q4(Mar 2024).Starting with the top line, the company reported a robust year-over-year sales growth of 15.23 %. However, it did see a marginal slip of -4.46 % from the previous quarter. Expenses decreased slightly by -0.6 % quarter-on-quarter, aligning with the annual rise of 19.64 %. Operating profit, while up 0.08 % compared to last year, faced a quarter-on-quarter dip of -17.58 %, signaling a short-term contraction in margins.
The Operating Profit Margin (OPM) % contradicts this narrative, showing weakness on an annual basis with a decrease of -2.96 %, but a shrinkage of -3.11 % sequentially. Other income rose by 244.38 % compared to the last quarter, despite an annual growth of 50.14 %. Interest expenses surged remarkably by 53.16 % from the previous quarter, yet the year-over-year increase remains at a moderate 98.36 %. Depreciation costs fell by -4.27 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 51.08 %. Profit before tax declined annually by -3.75 % but saw a reduction from the preceding quarter by -11 %.
Tax expenses as a percentage of profits increased slightly by 1.97 % compared to last year, with a more notable quarter-on-quarter decrease of -3.79 %. Net profit fell by -6.13 % year-on-year but witnessed a -6.42 % contraction from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual downturn of -12.18 % but a quarterly fall of -5.98 %. In summary, Marksans Pharma Ltd.’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 485.976 Cr | Rs. 586.127 Cr | Rs. 560.013 Cr | -4.46 % | + 15.23 % |
| Expenses | Rs. 376.43 Cr | Rs. 453.11 Cr | Rs. 450.37 Cr | -0.6 % | + 19.64 % |
| Operating Profit | Rs. 109.55 Cr | Rs. 133.02 Cr | Rs. 109.64 Cr | -17.58 % | + 0.08 % |
| Net Profit | Rs. 82.71 Cr | Rs. 82.97 Cr | Rs. 77.64 Cr | -6.42 % | -6.13 % |
| EPS in Rs | Rs. 1.97 | Rs. 1.84 | Rs. 1.73 | -5.98 % | -12.18 % |
In reviewing Marksans Pharma Ltd.’s 2024(Q4) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 15.23 % year-on-year growth, although there was a slight dip of -4.46 % from the previous quarter. Expenses rose by 19.64 % compared to the previous year, with a decrease of -0.6 % quarter-on-quarter. Operating Profit surged by 0.08 % annually, and saw a -17.58 % decrease from the last quarter.
Net Profit showed yearly decrease of -6.13 %, and experienced a -6.42 % decrease from the previous quarter. Earnings Per Share (EPS) fell by -12.18 % annually, however dipped by -5.98 % compared to the last quarter. In essence, while Marksans Pharma Ltd. faces strong annual decline indicators, short-term fluctuations suggest the need for agile strategies to navigate market dynamics effectively. That’s all for now in the financial sector.
